Primary Sclerosing Cholangitis — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
MLPH/RAB3A accelerates the differentiation of pancreatic stem cells to islet β-cells to control blood glucose in diabetic rats.
Shan Junling et al. — Organogenesis (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41774510/
- 2.
Subclinical psoriatic arthritis: concepts, dilemmas, and research needs.
Kharouf Fadi et al. — Annals of the rheumatic diseases (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41934034/
- 3.
Generative AI-Driven Accelerated Discovery of Passivation Molecules for Perovskite Solar Cells.
Fajar Adroit T N et al. — Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41926641/
- 4.
Partial occupation of selenium in porous carbon enhances selenium utilization for potassium-ion batteries.
Liu Lingli et al. — Chemical communications (Cambridge, England) (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41924981/
- 5.
Multiscale simulation of eco-friendly perovskites under space radiation.
Kareem Mustafa et al. — Nanoscale (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41769955/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
Completed — Phase 1 — National Cancer Institute (NCI)
https://clinicaltrials.gov/study/NCT00002912
- 2.
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Active (not recruiting) — Phase 2 — Mirum Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT04663308
- 3.
Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)
Completed — Phase 1 — Parvus Therapeutics, Inc.
https://clinicaltrials.gov/study/NCT06798454
- 4.
A Study of HTD1801 in Healthy Subjects
Completed — Phase 1 — HighTide Biopharma Pty Ltd
https://clinicaltrials.gov/study/NCT03099603
- 5.
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
Completed — Phase 2 — Pliant Therapeutics, Inc.
https://clinicaltrials.gov/study/NCT04480840
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis is a chronic progressive disease of the bile ducts characterised by inflammation and fibrosis, leading to strictures, liver failure, and a significantly elevated risk of cholangiocarcinoma. It is strongly associated with inflammatory bowel disease, particularly ulcerative colitis. No effective medical treatment exists; liver transplantation is the only definitive therapy for advanced disease.
Most Recent Research
BACKGROUND: This study aimed to determine the potential mechanism by which pancreatic stem cell-derived beta cells (PSCs-β) assist in the body's glucose-lowering capacity in type 1 diabetes (T1D) rats. METHODS: We screened the transcriptomic changes in the pancreatic islets of T1D mice to extract key genes from the GSE169275 dataset. Cell proliferation, cell cycle distribution, apoptosis, PSC-β differentiation ability, and insulin production levels were analyzed after MLPH overexpression/knockdown in PSCs. PSC-β-overexpressing MLPH were transplanted into T1D rats, and the changes in fasting blood glucose level, glucose tolerance and insulin, glucagon and C-peptide contents were examined. After the target genes of MLPH were analysed using the database, immunoprecipitation was introduced for validation. Whether RAB3A is involved in the regulatory effects of MLPH on the proliferation and differentiation of PSCs was further verified. RESULTS: MLPH overexpression further enhanced the proliferation of PSCs, inhibited apoptosis and accelerated the differentiation of PSCs to PSC-β cells and insulin secretion. After the transplantation of MLPH-overexpressing PSC-β cells, the pancreatic islet tissue damage was restored, the insulin expression was substantially elevated and the glucagon content decreased. RAB3A knockdown counteracted the effects of MLPH on the proliferation, differentiation and insulin secretion of PSCs. CONCLUSION: MLPH overexpression is favourable for the differentiation of PSCs to insulin β-cells. Transplantation of MLPH-overexpressing PSC-β cells restored the ability of T1D rats to manage a glycemic load by promoting RAB3A expression.
Common Questions
What is Primary Sclerosing Cholangitis?
Primary Sclerosing Cholangitis is a chronic progressive disease of the bile ducts characterised by inflammation and fibrosis, leading to strictures, liver failure, and a significantly elevated risk of cholangiocarcinoma. It is strongly associated with inflammatory bowel disease, particularly ulcerative colitis. No effective medical treatment exists; liver transplantation is the only definitive therapy for advanced disease.
How many clinical trials are available for Primary Sclerosing Cholangitis?
RareWays currently indexes 118 clinical trials for Primary Sclerosing Cholangitis, of which 27 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Primary Sclerosing Cholangitis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Primary Sclerosing Cholangitis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.